Agenus Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AGEN Nasdaq 2830 www.agenusbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Agenus Inc.

Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock? - Jan 13th, 2026 10:00 am
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas - Jan 12th, 2026 5:30 am
Agenus (AGEN) Q3 2024 Earnings Call Transcript - Jan 5th, 2026 4:24 pm
Agenus (AGEN) Q4 2024 Earnings Call Transcript - Jan 5th, 2026 2:52 pm
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC - Dec 23rd, 2025 6:05 am
Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight - Dec 1st, 2025 3:31 pm
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL - Nov 19th, 2025 2:01 pm
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC - Nov 18th, 2025 6:41 am
LGND: Target Up On Improved Growth Outlook - Nov 10th, 2025 8:05 am
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates - Nov 10th, 2025 6:40 am
Agenus: Q3 Earnings Snapshot - Nov 10th, 2025 5:37 am
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances - Nov 10th, 2025 5:30 am
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates - Nov 6th, 2025 3:20 pm
Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates - Nov 5th, 2025 4:40 pm
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report - Nov 5th, 2025 11:47 am
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates - Nov 3rd, 2025 3:20 pm
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025 - Oct 17th, 2025 6:00 am
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights - Oct 16th, 2025 5:48 am
Are Options Traders Betting on a Big Move in Agenus tock? - Sep 23rd, 2025 8:14 am
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer - Sep 9th, 2025 5:43 am